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Abstract In the absence of suitable rodent animal mod-
els for Plasmodium falciparummalaria, the efficacy testing
of asexual blood-stage vaccine candidates in Aotus nan-
cymaae represents a tool to select between different for-
mulations before conducting expensive human clinical
trials. CpG oligonucleotides (ODN) specifically promote
the production of pro-inflammatory and Th1-type cyto-
kines and they enhance the immunogenicity of co-admin-
istered antigens. Toll like receptor 9 (TLR-9) binds directly
and sequence-specifically to single-stranded un-methylated
CpG-DNA mediating the biological effects of CpG ODN.
We cloned and functionally characterised the TLR-9 cDNA
of A. nancymaae. The cDNA encompassed 3,099 bp pre-
dicted to code for 1,032 amino acid residues. Results of
homology searches to human TLR-9 suggested that the re-
ceptor is 93 and 94% identical at the nucleotide and amino
acid sequence levels, respectively. Stimulation of spleno-
cytes of A. nancymaae with CpG ODN resulted in prolifer-
ative responses in all animals analysed. FACS analysis of
cultures incubated with CpG ODN 2006 indicated that the
B cell marker CD20 was up-regulated consistent with B
cell activation. The high level of sequence conservation of
Aona-TLR-9 reinforces the suitability of A. nancymaae as
animal model for malaria subunit vaccine development.
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The vertebrate innate immune system recognises conserved,
pathogen-associatedmolecular patterns and responds through
the secretion and activation of a number of effector mole-
cules (Klinman 2004). Recognition of un-methylated CpG
di-nucleotides within specific flanking bases has evolved as
a pattern recognitionmechanism used by the innate immune
system to detect the DNA of pathogens (Klinman 2004).
The central involvement of the Toll like receptor 9 (TLR-9)
in responses to un-methylated CpG di-nucleotides has been
demonstrated using TLR-9-deficient mice (Hemmi et al.
2000). CpG DNA is bound directly by the TLR-9 in the
lysosomal compartment after cellular uptake (Cornelie et al.
2004; Latz et al. 2004; Rutz et al. 2004). B cells and plas-
macytoid dendritic cells are the main human cell types that
express TLR-9 and respond directly to CpG ODN stimu-
lation. Human memory B cells constitutively express high
levels of TLR-9 and proliferate and differentiate to immu-
noglobulin-secreting cells in response to CpG (Bernasconi
et al. 2003). CpG ODN interact with TLR-9 expressed by
plasmacytoid dendritic cells, improving antigen presenta-
tion and triggering the production of chemokines, Th1-type
and pro-inflammatory cytokines (including INF-γ, IL-6, IL-
12, IL-18 and TNF-α). Hence, CpGODN have great poten-
tial to be developed as adjuvant for T- and B-cell responses
(Klinman 2004).
At least three structurally distinct classes of CpG ODN
have been described in primates. K-type CpG ODN induce
strong B- and NK-cell activation, D-type ODN provoke
high levels of IFN-α secretion by plasmacytoid dendritic
cells, whilst C-type ODN combine properties of K- and
D-type ODN (Vollmer et al. 2004). Examples of K-type
include ODN 2006, an ODN with four “TCGT” motifs
separated by poly-T (Hartmann et al. 2000). Addition of
K-type ODN to vaccines against influenza virus, measles
virus, hepatitis B virus surface antigen or tetanus toxoid
increased antigen-specific antibody titres in mice by up to
The nucleotide sequence has been submitted to the GenBank nucle-
otide sequence database under the accession number AY788894.
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3 orders of magnitude (Klinman 2004). Optimal immuno-
stimulatory CpG DNA motifs differ between mouse and
human based on amino acid sequence variations between
the extracellular regions of TLR-9 (Bauer et al. 2001).
Therefore, experiments to determine whether a particular
CpG ODN may be of therapeutic benefit in humans are ini-
tiated in rodents, followed by evaluations in non-human
primates finally leading to phase I clinical trials (Cooper
et al. 2004; Krieg et al. 2004).
The development of a safe and effective malaria vaccine
remains an urgent medical need for human populations liv-
ing inmalaria-endemic regions (Malaney et al. 2004; Richie
and Saul 2002). Aotus nancymaae is one of the few permis-
sive hosts for the asexual forms of two major human ma-
laria parasites, Plasmodium falciparum and P. vivax (Gysin
1998). Immunisation and parasite challenge studies in A.
nancymaae can rationally support decisions concerning fur-
ther development of subunit malaria vaccines based on
H. sapiens MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSMAA 60 
A. nancymaae MGFCCSALHPLSLLVQAMMLAMTLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSVAA 60 
**** ************:***************************************:** 
H. sapiens PRGNVTSLSLSSNRIHHLHDSDFAHLPSLRHLNLKWNCPPVGLSPMHFPCHMTIEPSTFL 120 
A. nancymaae PRGNVTSLSLSSNRIHHLHDSDFAHLPSLRHLDLKWNCPPVGLSPMHFPCHMTIEPNTFL 120 
********************************:***********************.*** 
H. sapiens AVPTLEELNLSYNNIMTVPALPKSLISLSLSHTNILMLDSASLAGLHALRFLFMDGNCYY 180 
A. nancymaae AVPTLEELNLSYNSITAVPALPKSLVSLTLSRTNILVLDSASLAGLHALRFLFMDGNCYY 180 
*************.* :********:**:**:****:*********************** 
H. sapiens KNPCRQALEVAPGALLGLGNLTHLSLKYNNLTVVPRNLPSSLEYLLLSYNRIVKLAPEDL 240 
A. nancymaae KNPCRRALEVAPGALLGLGNLTHLSLKYNNLTVVPRNLPSSLEYLLLSYNHIIKLAPGDL 240 
*****:********************************************:*:**** **
H. sapiens ANLTALRVLDVGGNCRRCDHAPNPCMECPRHFPQLHPDTFSHLSRLEGLVLKDSSLSWLN 300 
A. nancymaae ANLTALRVLDVGGNCRRCDHAPNPCMECPRHFPQLHPNTFSHLSRLEGLVLKDSSLSWLN 300 
*************************************:**********************
H. sapiens ASWFRGLGNLRVLDLSENFLYKCITKTKAFQGLTQLRKLNLSFNYQKRVSFAHLSLAPSF 360 
A. nancymaae ASWFHGLGNLRVLDLSENFLYECITKTKAFQGLTQLRKLNLSFNYQKRVSFAHLSLAPSF 360 
****:****************:************************************** 
H. sapiens GSLVALKELDMHGIFFRSLDETTLRPLARLPMLQTLRLQMNFINQAQLGIFRAFPGLRYV 420 
A. nancymaae GSLFSLEELDMHGIFFRSLDETTLRPLARLSRLQTLHLQMNFINQAQLGIFGAFPGLRHV 420 
**.:*:***********************. ****:************** ******:*
H. sapiens DLSDNRISGASELTATMGEADGGEKVWLQPGDLAPAPVDTPSSEDFRPNCSTLNFTLDLS 480 
A. nancymaae DLSDNRISGASELAATTGEADGGGRVWLQPGDLAPAPVDAPSSEDFTANCSTLNFTLDLS 480 
*************:** ****** :**************:****** .************
H. sapiens RNNLVTVQPEMFAQLSHLQCLRLSHNCISQAVNGSQFLPLTGLQVLDLSHNKLDLYHEHS 540 
A. nancymaae RNNLVTVRPEMFARLSHLQCLRLSHNCIMQAVNGSQFLPLTDLRVLDLSHNKLDLYHEHS 540 
*******:*****:************** ************.*:****************
H. sapiens FTELPRLEALDLSYNSQPFGMQGVGHNFSFVAHLRTLRHLSLAHNNIHSQVSQQLCSTSL 600 
A. nancymaae FTELPRLEALDLSYNSQPFGMQGVGHNFSFVAHLRTLRYLSLAHNNIHSRVSPQLRSTSL 600 
**************************************:**********:** ** **** 
H. sapiens RALDFSGNALGHMWAEGDLYLHFFQGLSGLIWLDLSQNRLHTLLPQTLRNLPKSLQVLRL 660 
A. nancymaae RALDFSGNALGRMWAEGDLYLHFFQGLSGLIWLDLSQNSLHTLLPRTLGNLPKTLQVLRL 660 
***********:************************** ******:** ****:****** 
H. sapiens RDNYLAFFKWWSLHFLPKLEVLDLAGNQLKALTNGSLPAGTRLRRLDVSCNSISFVAPGF 720 
A. nancymaae RDNKLAFFKWRSLALLRKLEALDLAGNQLKALTNGSLPAMTRLRKLDVSCNSISFVAPGF 720 
*** ****** ** :* ***.****************** ****:***************
H. sapiens FSKAKELRELNLSANALKTVDHSWFGPLASALQILDVSANPLHCACGAAFMDFLLEVQAA 780 
A. nancymaae FSKAKKLRELNLSANALKTVDPSWFGPLVGALKILDVSTNPLHCACGAAFVDFLLEVQAA 780 
*****:*************** ******..**:*****:***********:********* 
H. sapiens VPGLPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFALSLLAVALGLGVPMLHHLCG 840 
A. nancymaae VPGLPSRVRCGSPAQLQGQSIFAQDLRLCLDEALSRDCFSFSLLAVALGLGVPLLHQLCG 840 
********:****.**** **************** ***::************:**:*** 
H. sapiens WDLWYCFHLCLAWLPWRGRQSGRDEDALPYDAFVVFDKTQSAVADWVYNELRGQLEECRG 900 
A. nancymaae WDLWYCFYLGLAWLPRWGRRGGRREDALPYDAFVVFDKAQSAVADWVYNELRRQLEECRG 900 
*******:* *****  **:.** **************:************* ******* 
H. sapiens RWALRLCLEERDWLPGKTLFENLWASVYGSRKTLFVLAHTDRVSGLLRASFLLAQQRLLE 960 
A. nancymaae RWALRLCLEERDWLPGKTLFENLWASVYGSRKTLFVLAHTDRVSGLLRASFLLAQQRLLE 960 
************************************************************ 
H. sapiens       DRKDVVVLVILSPDGRRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGMALTRDNHHF 1020 
A. nancymaae DRKDVVVLVILSPEGCRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGIALTGDNHHF 1020 
*************:* **********************************:*** ***** 
H. sapiens YNRNFCQGPTAE 1032 
A. nancymaae YNRNFCQGPTAE 1032 
************ 
aFig. 1 a Amino acid sequence
comparison of TLR-9 of
A. nancymaae and H. sapiens
using the ClustalW program
available at http://www.ebi.ac.
uk/clustalw/. Symbols “*”,“:”
and “.” indicate identical, con-
served and semi-conserved
amino acid residues, respec-
tively. Both sequences were
analysed for their domain struc-
ture using the SMART program
available at http://www.smart.
embl-heidelberg.de/. The pre-
dicted signal sequence is given
in italics, the leucine-rich repeat
region (LRR) is underlined and
the boxed sequences indicate the
Toll-interleukin 1-resistance do-
main (TIR). b Unrooted phylo-
genetic tree established from
deduced TLR-9 amino acid
sequences of Canis familiaris
(NP_001002998), Sus scrofa
(NP_999123), Rattus norvegi-
cus (NP_937764), Homo sa-
piens (NP_059138), Felis catus
(AAN15751), Mus musculus
(NP_112455) and A. nancymaae
AY788894 using the
neighbour-joining algorithm of
the PHYLIP 3.572 program
package available at http://www.
bioweb.pasteur.fr. The numbers
at the nodes indicate the per-
centage of recovery of that node
in 1,000 bootstrap replications
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distinct antigens, antigen combinations and antigen deliv-
ery systems (Chang et al. 1996). Aluminium compounds,
the only adjuvant used widely in humans, do not support the
development of Th1-type cell-mediated immune responses.
Since this arm of the cellular immune response seems to
play a central role in protection against a number of in-
fectious diseases including malaria (Gupta 1998), novel
approaches to develop vaccine formulations that induce
Th1-type and cytotoxic T cell responses are needed.
We carried out immunogenetic studies to characterise
the adaptive immune system of A. nancymaae in order to
define at the molecular level its suitability as an exper-
imental model in asexual blood-stage malaria vaccine de-
velopment (Daubenberger et al. 2001; Diaz et al. 2000a,b,
2002; Favre et al. 1998; Nino-Vasquez et al. 2000; Vecino
et al. 1999). In the current study, we characterised the
cDNA sequence of the TLR-9 of A. nancymaae (Aona-
TLR-9), followed by the description of in vitro stimulation
of A. nancymaae spleen cells by distinct CpG ODN. This
study was motivated by the hypothesis that CpG ODN
might have suitable adjuvant activity for the induction of
Th1-mediated immune responses in malaria vaccine devel-
opment (Jones et al. 1999). Additionally, a recent report
demonstrated that schizont extracts of P. falciparum may
contain a novel non-CpG ODN ligand binding to human
TLR-9. Investigations of this novel TLR-9 malaria parasite
interaction in a suitable animal model may lead to better
insights into early events in host–parasite interactions in
malaria (Pichyangkul et al. 2004).
The analysed animals were captured in the Colombian
Amazon area close to Leticia and kept at the experimental
primate station of the Fundacion Instituto de Immunologia
de Colombia (FIDIC) in accordance with the recommen-
dations of the Committee on Care and Use of Laboratory
Animals, US and theColombianNational Institute ofHealth
guidelines for use of laboratory animals and supervised by
theColombianWildlifeCorporation (CORPOAMAZONIA).
Mononuclear cells from three healthy monkeys numbered
as 23964, 23967 and 23968 were obtained by splenectomy
followed by density gradient separation. Total RNA was
Fig. 1 (continued)
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isolated from spleen cells of monkey 23968 and cDNA
synthesised as described (Daubenberger et al. 2001). Using
primer pairs designed according to the human TLR-9 se-
quence (GenBank accession number NM017442) and lo-
cated either outside (N- and C-terminal ends) or inside the
coding sequence, a set of overlapping RT-PCR products
were obtained which comprised the entire coding sequence
of A. nancymaae TLR-9 (Aona-TLR-9) cDNA. To exclude
possible PCR errors, all products were amplified from two
independently obtained cDNA, and at least four indepen-
dent plasmid preparations of each PCR amplification reac-
tion were sequenced. The total length of the Aona-TLR-9
open reading frame (ORF) was 3,099 bp coding for a pre-
dicted protein of 1,032 amino acids. The nucleotide and the
amino acid sequences displayed 93 and 94% identity, re-
spectively, to the human TLR-9. Alignment of the deduced
amino acid sequences of Aona-TLR-9 and human TLR-9 is
shown in Fig. 1a. A comparison of structural features using
the SMART architecture research programme http://www.
smart.embl-heidelberg.de) demonstrated that the structure of
Aona-TLR-9 is highly conserved to human TLR-9. Eigh-
teen leucine-rich repeats (LRR) were identified by the pro-
gramme, followed by one leucine-rich repeat C-terminal
domain and the toll interleukin 1-resistance domain (TIR)
encompassing residues 869 to 1,016 (Fig. 1a). A single-
nucleotide polymorphism of TLR-9 in human populations
has been described (Lazarus et al. 2003). One of the allelic
variants in humans carried at amino acid position 5 a cys-
teine instead of arginine (R5C). Alignment of human and
Aotus TLR-9 amino acid sequences demonstrated the same
sequence polymorphism (R5C) between these two species
(Fig. 1a). TLR-9 is a type I membrane receptor displaying
an N-terminal extracellular region abundant in leucine-rich
repeats, a cysteine-rich domain to the membrane, a single
transmembrane region and a cytoplasmic region comprising
the conserved TIR domain. A potential CpG-DNA binding
domain of TLR-9 located between amino acid residues 523
and 541 has been defined (Rutz et al. 2004). Introduction
of double alanine mutations (D535A and Y537A) strong-
ly diminished the CpG-sequence-specific DNA binding,
supporting the notion that the region containing D535 and
Y537 is involved in DNA binding. These two amino acid
residues are conserved between all full-length TLR-9 se-
quences available in the GeneBank including Aona-TLR-9.
Then we conducted a phylogenetic analysis incorporat-
ing all full-length TLR-9 sequences available at GenBank.
The analysis was performed employing the PHYLIP 3.572
software package available at http://www.bioweb.pasteur.fr
and the phylogenetic tree was constructed according to the
neighbour-joining method based on Kimura two-parameter
distances estimates (Saitou and Nei 1987). The results of
this analysis, shown in Fig. 1b, confirm that the TLR-9 of
human and Aotus are closely related, clustering together on
a separate branch and separated from rodent and carnivora
TLR-9 sequences.
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Fig. 2 Proliferative responses of
spleen cells of A. nancymaae to
CpG ODN 2006. A. nancymaae
spleen cells of three animals
were cultured in the absence or
presence of 6 μg/ml CpG ODN
for 72 h, pulsed during the last
16 h with [3H]thymidine and
incorporated radioactivity was
measured. Data represent mean
counts per minute (cpm) of
triplicate cultures and the stan-
dard error of means of triplicate
cultures was always <15%
Fig. 3 FACS analysis of A. nancymaae splenocytes after CpG ODN
incubation. Spleen cells were incubated for 96 h with medium alone
(dotted line), control CpG ODN IMT022 (black line) and ODN 2006
(filled graph) at 6μg/ml. Cells were removed from culture and stained
with anti-CD20 mAb B-Ly1 followed by incubation with FITC-
labelled anti-mouse IgG antibodies and analysed by FACS analysis
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Next, we wanted to demonstrate that CpG ODN activate
the spleen cells of A. nancymaae. It is well established that
K-type CpGODN induce proliferative responses via TLR-9
binding in B cells (Krieg et al. 1995). Therefore, we mea-
sured the proliferative responses of splenocytes upon in-
cubation with ODN 2006 and control ODN IMT022. The
K-type CpG ODN 2006 was chosen because of its previ-
ously described stimulatory activities in cells derived from
human, chimpanzee and rhesus monkey (Hartmann et al.
2000). As control, we included ODN IMT022 that has also
been described previously (Elias et al. 2003). Desalted
phosphoro-thioate oligonucleotides (ODN), HPLC-puri-
fied, were purchased from Metabion GmbH (Germany).
Purity was assessed by HPLC assays. ODNwere suspended
in HBSS buffer (Sigma) and kept at −20°C until use. A.
nancymaee spleen cells (1×105 cells/well) were stimulated
for 72 h with ODN 2006 and control ODN IMT022 at
6 μg/ml in 96-well round-bottomed plates or with medium
alone. Sixteen hours before harvest, [3H]thymidine was
added (1 μCi/well) into the cultures and the incorporated
radioactivity measured by scintillation counting. In cultures
of splenocytes of all three Aotus animals tested, ODN 2006
induced significant proliferative responses. The [3H]thy-
midine uptake in cultures incubated with control ODN
IMT022 was comparable to un-stimulated cultures, demon-
strating that the effect of ODN 2006 was dependent on a
distinct nucleotide sequence (Fig. 2).
In order to confirm that Aotus B cells were activated by
CpG ODN 2006, we analysed the changes in CD20 expres-
sion level. The CD20 molecule, also known as Bp35, is
expressed from the pre-B to mature B cell stages, and whilst
its precise functional role remains unknown, a role in B
cell activation, proliferation and differentiation is suggested
(Clark et al. 1985). Briefly, spleen cells of A. nancymaae
were cultivated at 3×105 cells/ml in cell culture medium in
48-well plates (Nunc) for 96 h in the presence of medium
alone or ODN 2006 or IMT022. Cells were recovered, trans-
ferred to FACS tubes and stained for flow cytometry with
the anti-CD20 mAb B-Ly1 (Pharmingen) (Daubenberger
et al. 2001). Cells were gated using forward and side scatter
parameters for dead cell exclusion and in each sample, 10,000
events weremeasured and data analysed using the CellQuest
software (BD Biosciences). As demonstrated in Fig. 3, in-
cubation of spleen cells with ODN2006 resulted in a shift of
the cell population to the right of the FL1-H axis. In cell
cultures incubated with medium and control ODN IMT022,
the mean fluorescence intensities were 180 and 141, re-
spectively, whilst in ODN 2006 treated cultures a value of
202 could bemeasured. Provided that mAbB-Ly1 stains the
CD20 homologue in A. nancymaae, these results indicate,
to our knowledge, for the first time that CD20 might be up-
regulated upon incubation of splenocytes with CpG ODN
2006.
In summary, the first complete TLR-9 cDNA sequence
of a non-human primate is described in this work. Aotus
monkeys immunised with a synthetic malaria peptide for-
mulated in CpG ODN 2006 responded with significantly
higher antibody levels compared to animals treated with con-
trol ODN (Jones et al. 1999). In combination with our mo-
lecular and functional characterisation of the Aona-TLR-9,
these results support the suitability of Aotus monkeys in the
analysis of CpG ODN as an adjuvant compound for sub-
unit-based vaccines against P. falciparum and P. vivax.
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